NFS 02
Alternative Names: NFS-02; rAAV2-ND1Latest Information Update: 22 Aug 2023
At a glance
- Originator Neurophth Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; NADH dehydrogenase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Leber's hereditary optic atrophy
Most Recent Events
- 17 Aug 2023 Phase-I/II clinical trials in Leber's hereditary optic atrophy in China (Intravitreous) (NCT05820152)
- 17 Aug 2023 Phase-I/II clinical trials in Leber's hereditary optic atrophy in USA (Intravitreous) (NCT05820152)
- 17 Apr 2023 NMPA approves IND application for NFS 02 in Leber's hereditary optic neuropathy